Synthesis of radioiodinated naltrindole analogues: Ligands for studies of delta opioid receptors

Chris M. Kinter; John R. Lever

doi:10.1016/0969-8051(94)00149-E

Synthesis of radioiodinated naltrindole analogues: Ligands for studies of delta opioid receptors

Chris M. Kinter, John R. Lever

School of Medicine

Research output: Contribution to journal › Article

Abstract

Analogues of naltrindole and N1′-methylnaltrindole having radioiodine in the 7′-position of the indole ring have been prepared for evaluation as delta opioid receptor ligands. The no-carrier-added radiosyntheses were conducted by Cu(I) assisted nucleophilic exchange of radioiodide for bromide under reducing conditions at 190 °C. A combination of HPLC and solid-phase extraction gave the ¹²⁵I- or ¹²³I-labeled products in satisfactory yields (47%) with high radiochemical purities (>98%) and high specific activities (¹²⁵I: 43-68 GBq/μmol, 1155-1833 mCi/μmol; ¹²³I: >92GBq/μmol, 2500mCi/μmol).

Original language	English (US)
Pages (from-to)	599-606
Number of pages	8
Journal	Nuclear Medicine and Biology
Volume	22
Issue number	5
DOIs	https://doi.org/10.1016/0969-8051(94)00149-E
State	Published - Jul 1995

ASJC Scopus subject areas

Molecular Medicine
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/0969-8051(94)00149-E

Fingerprint Dive into the research topics of 'Synthesis of radioiodinated naltrindole analogues: Ligands for studies of delta opioid receptors'. Together they form a unique fingerprint.

Cite this

Kinter, C. M., & Lever, J. R. (1995). Synthesis of radioiodinated naltrindole analogues: Ligands for studies of delta opioid receptors. Nuclear Medicine and Biology, 22(5), 599-606. https://doi.org/10.1016/0969-8051(94)00149-E

@article{3b21db54a1c4407cb5beba7da215721f,

title = "Synthesis of radioiodinated naltrindole analogues: Ligands for studies of delta opioid receptors",

abstract = "Analogues of naltrindole and N1′-methylnaltrindole having radioiodine in the 7′-position of the indole ring have been prepared for evaluation as delta opioid receptor ligands. The no-carrier-added radiosyntheses were conducted by Cu(I) assisted nucleophilic exchange of radioiodide for bromide under reducing conditions at 190 °C. A combination of HPLC and solid-phase extraction gave the 125I- or 123I-labeled products in satisfactory yields (47%) with high radiochemical purities (>98%) and high specific activities (125I: 43-68 GBq/μmol, 1155-1833 mCi/μmol; 123I: >92GBq/μmol, 2500mCi/μmol).",

author = "Kinter, {Chris M.} and Lever, {John R.}",

year = "1995",

month = jul,

doi = "10.1016/0969-8051(94)00149-E",

language = "English (US)",

volume = "22",

pages = "599--606",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Synthesis of radioiodinated naltrindole analogues

T2 - Ligands for studies of delta opioid receptors

AU - Kinter, Chris M.

AU - Lever, John R.

PY - 1995/7

Y1 - 1995/7

N2 - Analogues of naltrindole and N1′-methylnaltrindole having radioiodine in the 7′-position of the indole ring have been prepared for evaluation as delta opioid receptor ligands. The no-carrier-added radiosyntheses were conducted by Cu(I) assisted nucleophilic exchange of radioiodide for bromide under reducing conditions at 190 °C. A combination of HPLC and solid-phase extraction gave the 125I- or 123I-labeled products in satisfactory yields (47%) with high radiochemical purities (>98%) and high specific activities (125I: 43-68 GBq/μmol, 1155-1833 mCi/μmol; 123I: >92GBq/μmol, 2500mCi/μmol).

AB - Analogues of naltrindole and N1′-methylnaltrindole having radioiodine in the 7′-position of the indole ring have been prepared for evaluation as delta opioid receptor ligands. The no-carrier-added radiosyntheses were conducted by Cu(I) assisted nucleophilic exchange of radioiodide for bromide under reducing conditions at 190 °C. A combination of HPLC and solid-phase extraction gave the 125I- or 123I-labeled products in satisfactory yields (47%) with high radiochemical purities (>98%) and high specific activities (125I: 43-68 GBq/μmol, 1155-1833 mCi/μmol; 123I: >92GBq/μmol, 2500mCi/μmol).

UR - http://www.scopus.com/inward/record.url?scp=0029094002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029094002&partnerID=8YFLogxK

U2 - 10.1016/0969-8051(94)00149-E

DO - 10.1016/0969-8051(94)00149-E

M3 - Article

C2 - 7581169

AN - SCOPUS:0029094002

VL - 22

SP - 599

EP - 606

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 5

ER -